Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

被引：0

作者：

Crisa, Elena ^{[1
,2
]}

Mora, Elvira ^{[3
]}

Germing, Ulrich ^{[4
]}

Bally, Cecile ^{[5
]}

Campelo, Maria Diez ^{[6
]}

Myllymaki, Mikko ^{[7
,8
]}

Jadersten, Martin ^{[9
]}

Komrokji, Rami ^{[10
]}

Platzbecker, Uwe ^{[11
]}

Haase, Detlef ^{[12
]}

Hofmann, Wolf-Karsten ^{[13
]}

Al Ali, Najla H. ^{[10
]}

Barraco, Daniela ^{[2
,14
]}

Bargay, Juan Jose ^{[15
]}

Bernal, Teresa ^{[16
]}

Cadenas, Felix Lopez ^{[17
]}

Calvisi, Anna ^{[2
,18
]}

Capodanno, Isabella ^{[2
,19
]}

Cerrano, Marco ^{[20
,21
]}

Ciancia, Rosanna ^{[2
,22
]}

Crugnola, Monica ^{[2
,23
,24
]}

Kundgen, Andrea ^{[4
]}

Finelli, Carlo ^{[2
,25
]}

Fozza, Claudio ^{[2
,26
]}

Frairia, Chiara ^{[2
,21
]}

Freja, Ebeling ^{[27
]}

Ganster, Christina ^{[12
]}

Kubasch, Anne Sophie ^{[11
]}

Jimenez, Maria Jose ^{[28
]}

Latagliata, Roberto ^{[29
,30
]}

Mohedo, Francisca Hernandez ^{[31
]}

Molero, Antonieta ^{[32
]}

Pampliega, Miriam Vara ^{[33
]}

Perez, Clara Aparicio ^{[34
]}

Pietrantuono, Giuseppe ^{[2
,35
]}

Poloni, Antonella ^{[2
,36
]}

Pomares, Helena ^{[37
]}

Recasens, Valle ^{[38
]}

Rufer, Axel ^{[39
]}

Signori, Alessio ^{[40
]}

Hellstrom-Lindberg, Eva ^{[7
,8
]}

Fenaux, Pierre ^{[41
]}

Sanz, Guillermo ^{[6
,42
]}

Santini, Valeria ^{[2
,43
]}

机构：

[1] FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy

[2] Fdn Sindromi Mielodisplast FISiM ETS, Bologna, Italy

[3] Hosp Univ & Politecn La Fe, Inst Invest Sanitaria La Fe, Valencia, Spain

[4] Heinrich Heine Univ Dusseldorf, Univ Klin Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[5] Hop Necker Enfants Malad, AP HP, Hematol Clin, Paris, France

[6] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, Hematol, Salamanca, Spain

[7] Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland

[8] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland

[9] Karolinska Univ Hosp, Dept Hematol M64, Stockholm, Sweden

[10] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL USA

[11] Univ Hosp Leipzig, Dept Hematol Cellular Therapy Hemostaseol & Infect, Leipzig, Germany

[12] Univ Med Ctr Gottingen, Clin Hematol & Med Oncol, Gottingen, Germany

[13] Heidelberg Univ, Univ Hosp Mannheim, Dept Hematol & Oncol, Heidelberg, Germany

[14] Osped Circolo & Fdn Macchi, Dipartimento Ematol, ASST Sette Laghi, Varese, Italy

[15] Hosp Son Llatzer, Hematol Dept, Mallorca, Spain

[16] Hosp Cent Asturias, Hematol Dept, Oviedo, Spain

[17] Hosp Clin Univ Salamanca, Hematol Dept, Salamanca, Spain

[18] Osp San Francesco Nuoro, UOC Ematol CTMO, Nuoro, Italy

[19] SOC Ematol Azienda USL IRCSS Reggio Emilia, Reggio Emilia, Italy

[20] Univ Hosp Citta Salute & Sci, Hematol, Turin, Italy

[21] Hosp Citta Salute & Sci, Hematol, Turin, Italy

[22] IRCCS Ctr Riferimento Oncol CRO Aviano Pordenone, Aviano, Italy

[23] Univ Hosp Parma, Hematol Unit, Parma, Italy

[24] Univ Hosp Parma, BMT Ctr, Parma, Italy

[25] IRCCS Azienda Osped Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[26] Univ Sassari, Dept Clin & Expt Med, Sassari, Italy

[27] Helsinki Univ Cent Hosp, Dept Med, Helsinki, Finland

[28] Hosp Gemans Trias & Pujol, Hematol Dept, Badalona, Spain

[29] Osped Belcolle, Unita Operat Complessa UOC Ematol, Viterbo, Italy

[30] Sapienza Univ, Div Cellular Biotechnol & Hematol, Rome, Italy

[31] Hop Unversitario Virgen Nieves, Hematol Dept, Granada, Spain

[32] Hosp Univ Vall DHebron, Hematol Dept, Barcelona, Spain

[33] Hosp Cruces, Hematol Dept, Baracaldo, Spain

[34] Hosp Univ Reina Sofia, Hematol Dept, Cordoba, Spain

[35] IRCCS CROB, Referral Canc Ctr Basilicata, Rionero In Vulture, Italy

[36] Univ Politecn Marche AOU Marche, Hematol, Ancona, Italy

[37] ICO Duran & Reynals, Hematol Dept, Lhospitalet De LLobregat, Llobregat, Spain

[38] Hosp Miguel Servent, Valle Recasens Hematol Dept, Zaragoza, Spain

[39] Univ Luzern, Luzerner Kantonsspital, Div Hematol, Luzern, Switzerland

[40] Univ Genoa, Dept Hlth Sci, Sect Biostat, Genoa, Italy

[41] Hop St Louis, AP HP, Serv Hematol Seniors, Paris, France

[42] ISCIII, CIBERONC, Madrid, Spain

[43] Univ Florence, MDS Unit, Hematol, DMSC,AOU Careggi, Florence, Italy

来源：

LEUKEMIA | 2024年 / 38卷 / 10期

基金：

欧盟地平线“2020”;

关键词：

WORLD-HEALTH-ORGANIZATION; DEPENDENT PATIENTS; MYELOID NEOPLASMS; AML PROGRESSION; TP53; MUTATIONS; SCORING SYSTEM; RISK; MDS; MULTICENTER; LEUKEMIA;

D O I：

10.1038/s41375-024-02360-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lenalidomide (LEN) can induce red blood cell-transfusion independence (RBC-TI) in 60-70% of del(5q) myelodysplastic neoplasm (MDS) patients. Current recommendation is to continue LEN in responding patients until failure or progression, with likelihood of toxicity and a high cost for healthcare systems. This HARMONY Alliance study investigated the outcome of MDS del(5q) patients who discontinued LEN while RBC-transfusion independent. We enrolled 118 patients with IPSS-R low-intermediate risk. Seventy patients (59%) discontinued LEN for intolerance, 38 (32%) per their physician decision, nine (8%) per their own decision and one (1%) for unknown reasons. After a median follow-up of 49 months from discontinuation, 50/118 patients lost RBC-TI and 22/30 who underwent cytogenetic re-evaluation lost complete cytogenetic response. The median RBC-TI duration was 56 months. In multivariate analysis, RBC-TI duration after LEN discontinuation correlated with low transfusion burden before LEN therapy, treatment >= 12 LEN cycles, younger age and higher Hb level at LEN withdrawal. Forty-eight patients were re-treated with LEN for loss of response and 28 achieved again RBC-TI. These data show that stopping LEN therapy in MDS del(5q) patients who reached RBC-TI allows prolonged maintenance of TI in a large subset of patients.

引用

页码：2259 / 2265

页数：7

共 50 条

[21] Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study
Matsuda, Akira
Taniwaki, Masafumi
Jinnai, Itsuro
Harada, Hironori
Watanabe, Mitsumasa
Suzuki, Kenshi
Yanagita, Soshi
Suzuki, Takahiro
Yoshida, Yataro
Kimura, Akiro
Tsudo, Mitsuru
Tohyama, Kaoru
Takatoku, Masaaki
Ozawa, Keiya
LEUKEMIA RESEARCH, 2012, 36 (05) : 575 - 580
[22] Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
Al-Jafar, Hassan A.
Al-Azmi, Salih
Qassem, J. A.
Hasan, Eman A.
Alduaij, Arwa
CASE REPORTS IN ONCOLOGY, 2012, 5 (03): : 586 - 591
[23] Elderly patients with myelodysplastic syndrome with del 5q receiving lenalidomide: two case reports with poor prognosis
不详
ANNALES DE BIOLOGIE CLINIQUE, 2010, 68 (02) : 248 - 253
[24] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Sekeres, Mikkael A.
Swern, Arlene S.
Giagounidis, Aristoteles
List, Alan F.
Selleslag, Dominik
Mittelman, Moshe
Schlegelberger, Brigitte
Goehring, Gudrun
Li, Jack Shiansong
Sugrue, Mary M.
Fenaux, Pierre
BLOOD CANCER JOURNAL, 2018, 8
[25] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Mikkael A. Sekeres
Arlene S. Swern
Aristoteles Giagounidis
Alan F. List
Dominik Selleslag
Moshe Mittelman
Brigitte Schlegelberger
Gudrun Göhring
Jack Shiansong Li
Mary M. Sugrue
Pierre Fenaux
Blood Cancer Journal, 8
[26] LENALIDOMIDE (LEN) IN MYELODYSPLASTIC (MDS) DEL(5Q) PATIENTS: A SINGLE INSTITUTION POPULATION-BASED EXPERIENCE
Pelizzari, A.
Cerqui, E.
Schieppati, F.
Borlenghi, E.
Pagani, C.
Bellotti, D.
Rossi, G.
HAEMATOLOGICA, 2013, 98 : 580 - 580
[27] Lenalidomide is likely to improve overall survival in patients with del(5q) myelodysplastic syndrome with a complex karyotype.
Giagounidis, Aristoteles A.
Haase, Sabine
Germing, Ulrich
Goehring-Michaelsen, Gundula
Schlegelberger, Brigitte
Aul, Carlo
BLOOD, 2006, 108 (11) : 300B - 300B
[28] Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
Prebet, Thomas
Cluzeau, Thomas
Park, Sophie
Sekeres, Mikkael A.
Germing, Ulrich
Ades, Lionel
Platzbecker, Uwe
Gotze, Katharina
Vey, Norbert
Oliva, Esther
Sugrue, Mary M.
Bally, Cecile
Kelaidi, Charikleia
Al Ali, Najla
Fenaux, Pierre
Gore, Steven D.
Komrokji, Rami
ONCOTARGET, 2017, 8 (47) : 81926 - 81935
[29] MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE
Benettaib, B.
Lee, D.
Dhanasiri, S.
Brereton, N.
HAEMATOLOGICA, 2013, 98 : 310 - 310
[30] Cytopenias correlate with response to lenalidomide in del 5q MDS patients
Sekeres, M. A.
Maciejewski, J. P.
Giagounidis, A.
Wride, K.
Knight, R.
List, A.
LEUKEMIA RESEARCH, 2007, 31 : S37 - S38

← 1 2 3 4 5 →